Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome

Shigeru Saito, Mitchell W Krucoff, Shigeru Nakamura, Roxana Mehran, Akiko Maehara, Hussein R Al-Khalidi, Stephen M Rowland, Gudaye Tasissa, Debbie Morrell, Diane Joseph, Yumiko Okaniwa, Yoshisato Shibata, Barry D Bertolet, Mark D Rothenberg, Philippe Généreux, Hiram Bezerra, David F Kong, Shigeru Saito, Mitchell W Krucoff, Shigeru Nakamura, Roxana Mehran, Akiko Maehara, Hussein R Al-Khalidi, Stephen M Rowland, Gudaye Tasissa, Debbie Morrell, Diane Joseph, Yumiko Okaniwa, Yoshisato Shibata, Barry D Bertolet, Mark D Rothenberg, Philippe Généreux, Hiram Bezerra, David F Kong

Abstract

Aims: Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (HARMONEE) (NCT02073565) was a randomized pivotal registration trial of the Combo stent, which combined sirolimus and an abluminal bioabsorbable polymer with a novel endoluminal anti-CD34+ antibody coating designed to capture endothelial progenitor cells (EPC) and promote percutaneous coronary intervention (PCI) site healing.

Methods and results: Clinically stabilized PCI subjects were randomized 1:1 to receive Combo or everolimus-eluting stents (EES). Between February 2014 and June 2016, 572 subjects with 675 coronary lesions underwent 1-year angiography and fractional flow reserve, with optical coherence tomography (OCT) in the first 140 patients. The primary clinical endpoint was non-inferior 1-year target vessel failure (TVF). The primary mechanistic endpoint of EPC capture activity was superior strut coverage by OCT. Target vessel failure occurred in 7.0% Combo (20/287) vs. 4.2% EES (12/285), a 2.8% [95% confidence interval (95% CI) -1.0%, 6.5%] difference, meeting the non-inferiority hypothesis (P = 0.02). There were no cardiac deaths, with one stent thrombosis observed in the EES group. Quantitative coronary angiography late loss with Combo was equivalent to EES. Optical coherence tomography strut coverage at 1 year was superior with Combo vs. EES [91.3% (95% CI 88.7%, 93.8%) vs. 74.8% (95% CI 70.0%, 79.6%), P < 0.001], with homogeneous tissue in 81.2% vs. 68.8%, respectively.

Conclusion: Combo stent demonstrated non-inferior 1-year TVF and late loss in a randomized comparison to EES, with superior strut-based tissue coverage by OCT as a surrogate of EPC capture technology activity.

Figures

Figure 1
Figure 1
Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, FFR, and angiographic assessments. Cohort B: 12-month OCT, FFR, and angiographic assessments. Cohort C: 12-month FFR and angiographic assessments. EES, everolimus-eluting stent; FFR, fractional flow reserve; FU, follow-up; ITT, intention-to-treat; OCT, optical coherence tomography.
Figure 2
Figure 2
One-year Kaplan–Meier curves for target vessel failure (intention-to-treat population). CI, confidence interval; EES, everolimus-eluting stent; HR, hazard ratio.
Take home figure
Take home figure
Combo Stent Technology in HARMONEE. (A) Combo stent design: with abluminal bioabsorbable polymer-eluting sirolimus and endoluminal anti-CD34+ antibody. (B) Anti-CD34+ antibody mechanism of action: attracting CD34+ endothelial progenitor cells to stent site that mature to functional endothelium. (C) HARMONEE mechanistic ‘healthy endothelium’ surrogate superiority: representative images index procedure (baseline) and 1-year angiographic results with Combo and everolimus-eluting stents that are quantitatively similar, but optical coherence tomography at 1 year shows more complete strut coverage and more homogeneous tissue with Combo than with everolimus-eluting stent. EPC, endothelial progenitor cell; FU, follow-up; OCT, optical coherence tomography.
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6037087/bin/ehy275f3.jpg

References

    1. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012;125:2873–2891.
    1. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW.. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393–1402.
    1. Mauri L, Hsieh W-H, Massaro JM, Ho KKL, D’Agostino R, Cutlip DE.. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020–1029.
    1. Krucoff MW, Rutledge DR, Gruberg L, Jonnavithula L, Katopodis JN, Lombardi W, Mao VW, Sharma SK, Simonton CA, Tamboli HP, Wang J, Wilburn O, Zhao W, Sudhir K, Hermiller JB.. A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-marker study). JACC Cardiovasc Interv 2011;4:1298–1309.
    1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM.. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.
    1. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T.. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593–600.
    1. Haude M, Lee SW, Worthley SG, Silber S, Verheye S, Erbs S, Rosli MA, Botelho R, Meredith I, Sim KH, Stella PR, Tan HC, Whitbourn R, Thambar S, Abizaid A, Koh TH, Den Heijer P, Parise H, Cristea E, Maehara A, Mehran R.. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv 2013;6:334–343.
    1. Woudstra P, Kalkman DN, den Heijer P, Menown IB, Erglis A, Suryapranata H, Arkenbout KE, Ineguez A, van’t Hof AW, Muller P, Tijssen JG, de Winter RJ.. 1-year results of the REMEDEE Registry: clinical outcomes after deployment of the abluminal sirolimus-coated bioengineered (combo) stent in a multicenter, prospective all-comers registry. JACC Cardiovasc Interv 2016;9:1127–1134.
    1. Uchida T, Ikeno F, Ikeda K, Suzuki Y, Todaka K, Yokoi H, Thompson G, Krucoff M, Saito S.; Harmonization by Doing Program Working Group. Global cardiovascular device innovation: Japan-USA synergies: harmonization by Doing (HBD) program, a consortium of regulatory agencies, medical device industry, and academic institutions. Circ J 2013;77:1714–1718.
    1. Kong DF, Saito S, Nakamura S, Mehran R, Rowland SM, Handler A, Al-Khalidi HR, Krucoff MW.. Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich’s combo StEnt (Japan-USA HARMONEE): assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome. Am Heart J 2017;187:112–121.
    1. United States (U.S.) Food and Drug Administration (FDA). Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance. U.S. FDA web site. Updated April 1996. . (3 October 2017).
    1. International Medical Device Regulators Forum (IMDRF) Management Committee. Final Document International Medical Device Regulators Forum: Statement regarding Use of ISO 14155: 2011 “Clinical investigation of medical devices for human subjects – Good clinical practice.” IMDRF web site. Updated March 26, 2015. . (3 October 2017).
    1. Räber L, Jüni P, Nüesch E, Kalesan B, Wenaweser P, Moschovitis A, Khattab AA, Bahlo M, Togni M, Cook S, Vogel R, Seiler C, Meier B, Windecker S.. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. J Am Coll Cardiol 2011;57:2143–2151.
    1. Hasselblad V, Kong DF.. Statistical methods for comparison to placebo in active-control trials. Drug Inf J 2001;35:435–449.
    1. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, Steg PG, Morel M-A, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344–2351.
    1. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R.. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435–2441.
    1. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R.. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500–1510.
    1. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R.. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193–202.
    1. Ong ATL, McFadden EP, Regar E, de Jaegere PPT, van Domburg RT, Serruys PW.. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088–2092.
    1. Hwang WY, Foote J.. Immunogenicity of engineered antibodies. Methods 2005;36:3–10.
    1. Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW.. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol 2005;45:1206–1212.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa